SANDOZ CLOZAPINE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CLOZAPINE

から入手可能:

SANDOZ CANADA INCORPORATED

ATCコード:

N05AH02

INN（国際名）:

CLOZAPINE

投薬量:

25MG

医薬品形態:

TABLET

構図:

CLOZAPINE 25MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

ATYPICAL ANTIPSYCHOTICS

製品概要:

Active ingredient group (AIG) number: 0122583001; AHFS:

認証ステータス:

CANCELLED PRE MARKET

承認日:

2022-07-25

製品の特徴

_ _
_Sandoz Clozapine Page 1 of 53_
PRODUCT MONOGRAPH
PR
SANDOZ CLOZAPINE
Clozapine Tablets
25 mg and 100 mg tablets
Antipsychotic Agent
Sandoz Canada Inc.
Date of Revision:
110 rue de Lauzon
March 20, 2020
Boucherville, QC, Canada
J4B 1E6
Control No.: 237094
_ _
_Sandoz Clozapine Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
20
DRUG INTERACTIONS
..................................................................................................
25
DOSAGE AND ADMINISTRATION
..............................................................................
27
OVERDOSAGE
................................................................................................................
30
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 31
STORAGE AND STABILITY
..........................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 32
PART II: SCIENTIFIC INFORMATION
...............................................................................
33
PHARMACEUTICAL
INFORMATION..........................................................................
33
CLINICAL TRIALS
..........................................................................................................
34
DETAILED PHARMACOLOGY
..................................................